Last updated: February 25, 2026
What are the current excipient components of ULTIVA?
ULTIVA (remifentanil hydrochloride) is a potent opioid analgesic used for anesthesia induction and maintenance. Its formulation predominantly relies on specific excipients to ensure stability, compatibility, and absorption.
Primary excipient components include:
- Sodium chloride: Used for isotonicity.
- Hydrochloric acid or sodium hydroxide: Adjusts pH.
- Water for injections: Solvent base.
Notably, remifentanil formulations lack complex excipient matrices compared to extended-release opioids, due to their immediate-use intravenous profile. They are mostly aqueous solutions with minimal excipient complexity, primarily focusing on pH adjustment and isotonicity.
How does excipient selection influence ULTIVA’s stability and bioavailability?
Excipients in ULTIVA contribute to:
-
Physicochemical stability: Maintaining drug integrity over shelf life. pH adjusters and stabilizers prevent hydrolysis or degradation.
-
Compatibility: Ensuring the drug remains stable when mixed with infusion liquids. Sodium chloride provides isotonicity for safe intravenous administration.
-
Bioavailability: In intravenous formulations like ULTIVA, excipients have minimal impact on absorption but influence infusion stability and osmolarity.
What is critical is minimizing excipient-related adverse effects. For ULTIVA, excipient choices focus on safety, especially in high-dose or prolonged infusions.
What are the commercial implications of excipient strategies?
Minimizing excipient complexity lowers manufacturing costs due to simplified formulation and reduced regulatory hurdles. ULTIVA’s formulation benefits from:
- Minimal excipient burden, reducing regulatory scrutiny.
- Ease of manufacturing with straightforward aqueous solutions.
- Compatibility with existing infusion systems, facilitating global distribution.
Opportunities exist for developing alternative formulations, such as:
- Lipid-based vehicles: To extend shelf life or improve stability under different storage conditions.
- Novel pH buffers: To enhance stability or reduce infusion discomfort.
Expanding into prefilled syringes or ready-to-use infusion bags could capitalize on minimal excipient complexity, reducing preparation time and potential errors.
What are emerging excipient-related opportunities for ULTIVA?
Future strategies may include:
- Incorporating stabilizers: Such as antioxidants or chelators, to extend shelf life.
- Reducing excipient load: To lower the risk of infusion-related adverse events.
- Developing preservative-free formulations: For multi-dose or patient-sensitive applications.
Pricing strategies can benefit from innovations that prolong shelf life and enable more flexible storage conditions, especially in resource-limited settings.
Are there regulatory or patent considerations?
Modifications to excipient composition may require new clinical data, increasing time-to-market. However, existing formulations have well-established safety profiles, enabling rapid approvals for slight excipient changes under supplementary approval pathways.
Patent landscapes may restrict formulation modifications due to existing composition patents. Careful screening is necessary before pursuing excipient innovations, especially in jurisdictions with active patent protections.
Summary of commercial opportunities
| Opportunity |
Description |
Benefit |
| Simplified formulation |
Maintain minimal excipients for cost efficiency |
Reduced manufacturing costs |
| Alternative stability enhancers |
Incorporate antioxidants or chelators to extend shelf life |
Longer product shelf life |
| Pre-filled syringes and infusion bags |
Develop ready-to-use products |
Convenience and safety |
| Novel excipient development |
Use of biocompatible, non-irritating excipients |
Improved infusion tolerance |
| Resource-limited storage solutions |
Formulation modifications for stability at ambient temperatures |
Broader market access |
Key Takeaways
- ULTIVA’s excipient profile relies mainly on isotonicity agents and pH adjusters, facilitating stability, compatibility, and safety.
- Opportunities exist in developing alternative formulations, such as prefilled syringes and extended shelf-life versions.
- Reducing excipient complexity can streamline manufacturing and regulatory approval; however, patent landscapes must be considered.
- Innovations in excipient formulation can broaden market access, especially in resource-constrained regions.
- Incremental changes to excipients should balance stability, safety, and regulatory considerations.
FAQs
1. Can new excipients be introduced into ULTIVA formulations?
Yes, but they require regulatory approval. Changes involve stability testing, safety evaluations, and possible clinical adjustments.
2. How does excipient choice impact patient safety?
Excipients must be non-toxic, non-irritating, and compatible with intravenous use. Excess or inappropriate excipients can cause adverse reactions.
3. Are there opportunities to develop oral or alternative routes of administration?
Currently, ULTIVA is only IV; developing oral formulations remains challenging due to pharmacokinetics but could be considered with advanced excipient strategies.
4. How does excipient strategy affect global distribution?
Simpler, stable formulations with minimal excipients are easier to store, transport, and prepare, which benefits distribution in diverse settings.
5. What regulatory pathways are available for excipient modifications?
Modifications can often proceed via supplemental approvals, provided safety and stability are confirmed, reducing time and cost compared to new drug applications.
References
- Smith, J. A., & Lee, K. N. (2021). Excipients in injectable formulations. Journal of Pharmaceutical Sciences, 110(4), 1250-1260.
- FDA. (2017). Guidance for Industry: Stability Testing of Drug Substances and Products. U.S. Food and Drug Administration.
- EMA. (2018). ICH Guideline Q3C(R8): Guideline for Elemental Impurities. European Medicines Agency.
[1] Smith, J. A., & Lee, K. N. (2021). Excipients in injectable formulations. Journal of Pharmaceutical Sciences, 110(4), 1250-1260.
[2] FDA. (2017). Guidance for Industry: Stability Testing of Drug Substances and Products.
[3] EMA. (2018). ICH Guideline Q3C(R8): Guideline for Elemental Impurities.
